{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Brennan FR"],"funding":["HESI scientific initiative"],"pubmed_abstract":["Therapeutic monoclonal antibodies (mAbs) are often designed to not only bind targets via their antigen-binding domains (Fabs) but to also engage with cell surface receptors, FcγRs and FcRn, through their Fc regions, which may result in a variety of functional outcomes, including antibody- dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and alteration of circulating half-lives. Engineering the Fc regions to achieve desirable pharmacology and pharmacokinetics is a widely adopted strategy in drug development. Fc regions can be modified through amino acid substitutions and glycoengineering, resulting in enhanced or reduced effector functions, preferential binding to FcR subtypes, or pH-dependent binding to FcRns. "],"journal":["mAbs"],"pagination":["2505092"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12239809"],"repository":["biostudies-literature"],"pubmed_title":["Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies."],"pmcid":["PMC12239809"],"pubmed_authors":["Struthers M","Andersen JT","Manetz TS","Brinkhaus M","Flora A","Stefanich E","Mitchell-Ryan S","Wensel DL","Sathish J","Humphreys DP","Wolf B","Ramones M","Dzielak L","Sharda N","Balbino B","Wang X","Fogal B","Brennan FR","Polli JR","Ji C","Price K","Soper B","Peters SJ","Witcher D","Schlothauer T","Honda M","Maier CC","Doyle M","Ryan PC","Shastri PN"],"additional_accession":[]},"is_claimable":false,"name":"Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.","description":"Therapeutic monoclonal antibodies (mAbs) are often designed to not only bind targets via their antigen-binding domains (Fabs) but to also engage with cell surface receptors, FcγRs and FcRn, through their Fc regions, which may result in a variety of functional outcomes, including antibody- dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and alteration of circulating half-lives. Engineering the Fc regions to achieve desirable pharmacology and pharmacokinetics is a widely adopted strategy in drug development. Fc regions can be modified through amino acid substitutions and glycoengineering, resulting in enhanced or reduced effector functions, preferential binding to FcR subtypes, or pH-dependent binding to FcRns. ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-15T10:51:27.318Z","creation":"2026-07-03T03:15:36.697Z"},"accession":"S-EPMC12239809","cross_references":{"pubmed":["40624840"],"doi":["10.1080/19420862.2025.2505092"]}}